GlassScriptPhysician profile
Goonja Patel
NPI 1912526047
$2,016.19
in general payments reported to CMS, 2019-2025
14 companies · $2,016 in 2025
The $2,016 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $526.84 | 2025 | Minimed 780g, Pteye Parathyroid Detection System |
| Novo Nordisk INC | $315.33 | 2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $299.58 | 2025 | Evenity, Tepezza, Prolia |
| Corcept Therapeutics | $213.17 | 2025 | Korlym |
| Insulet Corporation | $150.27 | 2025 | Omnipod |
| Lilly USA, LLC | $118.79 | 2025 | Zepbound, Jardiance |
| Recordati_rare_diseases_inc. | $97.43 | 2025 | Isturisa |
| Radius Health, INC. | $77.04 | 2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $62.68 | 2025 | |
| Xeris Pharmaceuticals, INC. | $45.52 | 2025 | Recorlev |
| Tandem Diabetes Care, INC. | $40.29 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $28.12 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $22.08 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $19.05 | 2025 | Imcivree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Goonja Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.